摘要
目的探讨轻型颅脑损伤(mild traumatic brain injury,mTBI)后患者血清胶质细胞纤维酸性蛋白分解产物(glial fibrillary acidic protein breakdown products,GFAP-BDPs)含量的临床意义和患者预后关系。方法用ELISA法检测47例轻型颅脑损伤患者血清GFAP-BDPs含量并与20例体检健康患者比较。对比27例头颅CT阴性和20例头颅CT阳性mTBI患者血清GFAP-BDPs含量。评估患者6个月后GOS-E评分和mTBI患者血清GFAP-BDPs含量的关系。结果轻型颅脑损伤患者血清GFAP-BDPs含量高于正常对照组(P<0.05)。结论血清GFAP-BDPs可作为轻型颅脑损伤诊断的生物标志物,对鉴别mTBI患者后头颅CT阳性和阴性患者有一定准确性,血清GFAP-BDPs含量越高患者预后越差。
Objective To explore the relationship of clinical significance and prognosis between patients with mild traumatic brain injury （mTBI） and glial fibrillary acidic protein breakdown products （GFAP-BDPs） change. Methods Detected by ELISA in 47 cases of mild head injury patients and 20 healthy subjects serum GFAP-BDPs content,and the results were compared. Comparison the serum concentrations of GFAP-BDPs between the 27 cases of head CT negative mTBI patients and the 20 cases of head CT positive mTBI patients. The relationship was assessed between the GOS-E score of mTBI patient after 6 months and the concentrations of GFAP-BDPs in the serum of patients. Results Serum of patients with mild head injury GFAP-BDPs were significantly higher than that of the control group （ P 〈 0.05）. Conclusion GFAP-BDPs serum can be used as diagnostic biomarkers of mTBI, It has a certain accuracy that serum GFAP-BDPs levels can identify patients with positive and negative head CT; The higher levels of serum GFAP-BDPs worse prognosis.
出处
《外科研究与新技术》
2014年第1期24-27,共4页
Surgical Research and New Technique
